Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $0.3 | $0.5 | ($0.7) | $0.9 | $1.1 | $1.5 | $1.7 | $1.8 | $1.7 | $2.0 | $8.0 | $12.4 | $10.1 | $3.5 | $4.2 | $4.2 | $0.1 | $5.0 | $3.7 | $4.5 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Gilead Sciences, Inc.'s last 12-month EPS is $0.1, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Gilead Sciences, Inc.'s EPS growth was (97.9%). The average annual EPS growth rates for Gilead Sciences, Inc. have been (26.3%) over the past three years, (45.7%) over the past five years.
Over the last year, Gilead Sciences, Inc.'s EPS growth was (97.9%), which is lower than industry growth of (0.2%). It indicates that Gilead Sciences, Inc.'s EPS growth is Bad.